期刊文献+

相关凋亡基因在多发性骨髓瘤发病中作用的研究进展

The Role of related apoptosis gene in the pathogenesis of multiple myeloma
原文传递
导出
摘要 多发性骨髓瘤(MM)是浆细胞克隆性增生的恶性肿瘤,是一种低增殖性、低凋亡活性的分子克隆性疾病,这一特点提示凋亡抑制可能在其发病中发挥了重要的作用。因此,研究MM发病过程中相关的促凋亡基因(蛋白)和抑凋亡基因(蛋白)以及它们之间的相关性,将为MM的分子靶向治疗提供新的策略。 Multiple myeloma (MM) is a clonal plasma cell malignancy, a low proliferative and low apoptotic activity molecular cloning of a disease, which indicates that apoptosis inhibition may play an important role in the pathogenesis of MM. Therefore, the study of MM pathogenesis-related promoting apoptosis genes/proteins and inhibiting of apoptosis genes/proteins, as well as the correlation between them provides a new strategy for molecular targeted therapy.
出处 《白血病.淋巴瘤》 CAS 2010年第8期509-512,共4页 Journal of Leukemia & Lymphoma
关键词 多发性骨髓瘤 细胞凋亡 SURVIVIN SMA 研究 Multiple myeloma Apoptosis Survivin Smac Research
  • 相关文献

参考文献5

二级参考文献51

  • 1王学文,杨天楹.难治性和复发性骨髓瘤的治疗进展[J].国外医学(输血及血液学分册),1993,16(1):35-37. 被引量:11
  • 2李娟,赵莹,张殿宝,黄蓓晖.Survivin在多发性骨髓瘤患者骨髓细胞中的表达及其临床意义[J].癌症,2005,24(12):1522-1526. 被引量:13
  • 3包悍英,蔡真.survivin mRNA表达水平与高三尖杉酯碱诱导恶性血液病细胞凋亡的相关性研究[J].浙江大学学报(医学版),2006,35(2):204-208. 被引量:3
  • 4张燕,徐从高,马道新,王向玲,王兴武.不同血液肿瘤细胞株survivin基因和蛋白表达及意义的研究[J].山东大学学报(医学版),2006,44(6):593-596. 被引量:2
  • 5Rock E P, Goodman V, Jiang J X et al. Food and drug adminstration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma[J]. Oncologist,2007; 12 (1):107-113.
  • 6Goodman V L, Rock E P, Dagher R et al. Approval summary sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advancedrenal cell carcinoma [ J ]. Clin Cancer Res, 2007 ; 13 (5) : 1367-1373.
  • 7Motzer R J, Michaelson M D, Redman B Get al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma [J]. J CIin Oncol,2006;24( 1): 16-24.
  • 8Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral muhitarget tyrosine kinase inhibitor, in patients with cancer [ J ]. J Clin Oncol, 2006 ; 24 ( I ) : 25-35.
  • 9Fiedler W, Serve H, Dohner H et al. A phase Ⅰ study of SU11248 in tile treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease [J]. Blood,2005 ; 105(3) :986-993.
  • 10Chow L Q. Eckhardt S G. Sunitinib: from rational design to clinical efficacy[J] .J Clin Oncol,2007;25(7):884-896.

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部